Evidence map›Paper›PMID 30337678›Full record

ArticleScientific reports2018

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Matthew Ezewudo, Amanda Borens, Álvaro Chiner-Oms, Paolo Miotto, Leonid Chindelevitch, Angela M Starks, Debra Hanna, Richard Liwski, Matteo Zignol, Christopher Gilpin and 19 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 3 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Open-access genomic drug resistance prediction tools forJournal of clinical microbiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 19 institutions in 12 countries.

Matthew EzewudoCritical Path Institute, 1730 E River Rd., Tucson, AZ, 85718, USA.
Amanda BorensCritical Path Institute, 1730 E River Rd., Tucson, AZ, 85718, USA.ORCID http://orcid.org/0000-0002-5695-3463
Álvaro Chiner-OmsJoint unit Infection and Public Health FISABIO-CSISP/University of Valencia, Institute of integrative Systems Biology, Valencia, Spain.ORCID http://orcid.org/0000-0002-0463-0101
Paolo MiottoEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, via Olgettina 58, 20132, Milano, Italy.ORCID http://orcid.org/0000-0003-4610-2427
Leonid ChindelevitchSchool of Computing Science, Simon Fraser University, 8888 University Ave, Burnaby, BC, V5A 1S6, Canada.
Angela M StarksDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road MS F08, Atlanta, GA, 30329, USA.
Debra HannaCritical Path Institute, 1730 E River Rd., Tucson, AZ, 85718, USA.
Richard LiwskiCritical Path Institute, 1730 E River Rd., Tucson, AZ, 85718, USA.
Matteo ZignolGlobal Tuberculosis Program, World Health Organization, Geneva, Switzerland.
Christopher GilpinGlobal Tuberculosis Program, World Health Organization, Geneva, Switzerland.
Stefan NiemannGerman Center for Infection Research, Partner Site Borstel, Borstel, Germany.
Thomas Andreas KohlMolecular and Experimental Mycobacteriology, Priority area Infections, Research Center Borstel, Borstel, Germany.
Robin M WarrenDST/NRF Centre of Excellence for Biomedical Tuberculosis Research/SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Derrick CrookNuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, United Kingdom.
Sebastien GagneuxSwiss Tropical and Public Health Institute, Basel, Switzerland.
Sven HoffnerDepartment of Public Health Sciences, Karolinska institute, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-3168-2863
Camilla RodriguesHinduja Hospital, Veer Savarkar Marg, Mahim, Mumbai, India.
Iñaki ComasTuberculosis Genomics Unit, Biomedicine Institute of Valencia (IBV-CSIC), Street Jaime Roig 11. P.O., 4010, Valencia, Spain.ORCID http://orcid.org/0000-0001-5504-9408
David M EngelthalerTranslational Genomics Research Institute, 3051 W. Shamrell Blvd. Ste 106, Flagstaff, AZ, 86005, USA.
David AllandCenter for Emerging Pathogens, Rutgers-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ, 07103, USA.
Leen RigoutsDepartment of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Christoph LangeDivision of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany.
Keertan DhedaLung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Old Main Building, Groote Schuur Hospital, Observatory, Cape Town, South Africa.
Rumina HasanDepartment of Pathology and Laboratory Medicine, Aga Khan University, Stadium Road, Karachi, Pakistan.
Ruth McNerneyDepartment of Medicine, Division of Pulmonology, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-0505-2291
Daniela M CirilloEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, via Olgettina 58, 20132, Milano, Italy.
Marco SchitoCritical Path Institute, 1730 E River Rd., Tucson, AZ, 85718, USA.
Timothy C RodwellDepartment of Medicine, University of California, San Diego, CA, USA.
James PoseyDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road MS F08, Atlanta, GA, 30329, USA. hzp9@cdc.gov.
Critical Path Institute · USCenters for Disease Control and Prevention · USGerman Center for Infection Research · DEUniversity of Cape Town · ZAVita-Salute San Raffaele University · ITWorld Health Organization · CHAga Khan University · PKFIND · CHInstituut voor Tropische Geneeskunde · BEJohn Radcliffe Hospital · GBKarolinska Institutet · SEP. D. Hinduja Hospital and Medical Research Centre · INResearch Center Borstel - Leibniz Lung Center · DERutgers, The State University of New Jersey · USSimon Fraser University · CASouth African Medical Research Council · ZASwiss Tropical and Public Health Institute · CHTranslational Genomics Research Institute · USUniversitat de València · ES

Funding

European Research Council 638553Medical Research Council MC_PC_16027World Health Organization 001
6 · The paper itself

Abstract

Drug-resistant tuberculosis poses a persistent public health threat. The ReSeqTB platform is a collaborative, curated knowledgebase, designed to standardize and aggregate global Mycobacterium tuberculosis complex (MTBC) variant data from whole genome sequencing (WGS) with phenotypic drug susceptibility testing (DST) and clinical data. We developed a unified analysis variant pipeline (UVP) ( https://github.com/CPTR-ReSeqTB/UVP ) to identify variants and assign lineage from MTBC sequence data. Stringent thresholds and quality control measures were incorporated in this open source tool. The pipeline was validated using a well-characterized dataset of 90 diverse MTBC isolates with conventional DST and DNA Sanger sequencing data. The UVP exhibited 98.9% agreement with the variants identified using Sanger sequencing and was 100% concordant with conventional methods of assigning lineage. We analyzed 4636 publicly available MTBC isolates in the ReSeqTB platform representing all seven major MTBC lineages. The variants detected have an above 94% accuracy of predicting drug based on the accompanying DST results in the platform. The aggregation of variants over time in the platform will establish confidence-graded mutations statistically associated with phenotypic drug resistance. These tools serve as critical reference standards for future molecular diagnostic assay developers, researchers, public health agencies and clinicians working towards the control of drug-resistant tuberculosis.

Indexed as

MutationAntitubercular AgentsBacterial ProteinsDrug Resistance, Multiple, BacterialGenome, BacterialGenotypeHumansKnowledge BasesMycobacterium tuberculosisPolymorphism, Single NucleotideSequence Analysis, DNATuberculosis, Multidrug-ResistantWhole Genome SequencingAntitubercular AgentsBacterial Proteins

Identifiers

PMID30337678
PMCPMC6194142
OpenAlexW2896693913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.